Search results for "Psychosi"

showing 10 items of 330 documents

A Multicentre, Randomised, Controlled Trial of a Combined Clinical Treatment for First-Episode Psychosis

2021

Introduction: There is evidence that early intervention contributes to improving the prognosis and course of first-episode psychosis (FEP). However, further randomised treatment clinical trials are needed. Objectives: The aim of this study was to compare the efficacy of a combined clinical treatment involving Cognitive Behavioural Therapy (CBT) as an adjunctive to treatment-as-usual (TAU) (CBT+TAU) versus TAU alone for FEP. Patients and methods: In this multicentre, single-blind, randomised controlled trial, 177 participants were randomly allocated to either CBT+TAU or TAU. The primary outcome was post-treatment patient functioning. Results: The CBT+TAU group showed a greater improvement in…

Psychosismedicine.medical_specialtyanimal structuresPronòstic mèdicHealth Toxicology and MutagenesisPsicosiDiseasebehavioral disciplines and activitiesArticlelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawIntervention (counseling)Internal medicinemental disordersmedicineScopusHumansSingle-Blind Methodfirst-episode psychosisClinical treatmenttreatmentCognitive Behavioral Therapybusiness.industryStandard treatmentRPublic Health Environmental and Occupational HealthPsychosesCognitionmedicine.diseasePrognosisCombined Modality Therapy030227 psychiatryClinical trialTreatment Adherence and Complianceearly interventionTreatment OutcomePsychotic DisordersJCRSchizophreniaoutcomeMedicineEsquizofrèniabusinessrandomised controlled trial030217 neurology & neurosurgeryInternational Journal of Environmental Research and Public Health
researchProduct

O12.4. SOME OF THE INDIVIDUAL DIFFERENCES IN RISK TO DEVELOP PSYCHOSIS AMONG CANNABIS USERS CAN BE EXPLAINED BY WHERE THEY LIVE AND BY THEIR AGE AT F…

2018

Abstract Background Cannabis use remains the most widely used recreational drug worldwide. Following from several USA states legalisation policies, European countries are reconsidering their cannabis laws. While a significant amount of Epidemiological evidence has reported that cannabis use increases the risk of psychosis it is still unclear: 1) what underpins individual differences in developing a psychotic disorder following cannabis use; 2) if variations in availability of cannabis have affected rate of Psychotic disorders across Europe. Methods Using detailed data on lifetime pattern of cannabis use from the EUGEI first episode case-control study (N=2300) and the available Incidence rat…

Psychosismedicine.medical_specialtybiologymedicine.diseasebiology.organism_classification030227 psychiatryAbstracts03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineO12. Oral Session: Socio-Economic/EnvironmentmedicineCannabisPsychiatryPsychology030217 neurology & neurosurgerySchizophrenia Bulletin
researchProduct

Naturalistic follow-up study of rehospitalization rates and assigned disability status of patients with first-episode schizophrenia spectrum psychosi…

2020

Patients with first-episode schizophrenia spectrum psychosis (FEP) are at risk of not visiting an out-patient psychiatrist and are assigned disability status within a short period after diagnosis.The aim of this study was to conduct a naturalistic follow-up of FEP patients to explore their use of mental healthcare services and the rate of assigned disability status after FEP.This was the first study in Latvia to include all consecutive patients with FEP admitted to the largest regional hospital in South East Latvia, Daugavpils Psychoneurological Hospital (DPNH). Patients received standard treatment in a real-world environment. The mean follow-up time was 33 months (Min = 20 months, Max = 40…

Psychosismedicine.medical_specialtybusiness.industryFollow up studiesFirst episode schizophreniamedicine.diseasebehavioral disciplines and activitiesLatviaHospitalizationPsychiatry and Mental healthPsychotic DisordersSchizophreniamental disordersSouth eastmedicineSchizophreniaHumansPsychiatrybusinessSchizophrenia spectrumFollow-Up StudiesNordic journal of psychiatry
researchProduct

Pre-training inter-rater reliability of clinical instruments in an international psychosis research project.

2021

International audience

Research designPsychosisINFORMATIONIMPACTApplied psychologyMEDLINEAssessor selection Pre-training inter-rater reliability Psychosis instruments03 medical and health sciences0302 clinical medicineMedicineHumansBiological PsychiatryComputingMilieux_MISCELLANEOUSObserver VariationREPRODUTIBILIDADE DE RESULTADOSbusiness.industryPre-training inter-rater reliabilityReproducibility of Resultsmedicine.disease030227 psychiatryPsychiatry and Mental healthInter-rater reliabilityAssessor selectionTRIALSPsychotic DisordersResearch Design[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]MEASUREMENT ERRORbusinessObserver variation030217 neurology & neurosurgeryPsychosis instrumentsSchizophrenia research
researchProduct

Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway

2022

AbstractBackgroundThere is evidence that environmental and genetic risk factors for schizophrenia spectrum disorders are transdiagnostic and mediated in part through a generic pathway of affective dysregulation.MethodsWe analysed to what degree the impact of schizophrenia polygenic risk (PRS-SZ) and childhood adversity (CA) on psychosis outcomes was contingent on co-presence of affective dysregulation, defined as significant depressive symptoms, in (i) NEMESIS-2 (n = 6646), a representative general population sample, interviewed four times over nine years and (ii) EUGEI (n = 4068) a sample of patients with schizophrenia spectrum disorder, the siblings of these patients and controls.ResultsT…

RiskMultifactorial InheritancePsychosisHallucinationsAffective pathwayCLINICAL PSYCHOSISNEGATIVE SYMPTOMSDelusions03 medical and health sciences0302 clinical medicineMENTAL-HEALTH SURVEYchildhood adversityAffective dysregulationHumansMedicinegeneticspsychosisGenetic riskApplied Psychology1ST EPISODE PSYCHOSISGENERAL-POPULATIONbusiness.industryPSYCHIATRIC-DISORDERSSHORT-FORMAbsolute risk reductionNETWORK APPROACHIdeationmedicine.diseaseCHILDHOOD TRAUMA030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaSCHIZOPHRENIA SPECTRUM DISORDERSPolygenic risk scorebusinessenvironment030217 neurology & neurosurgerySchizophrenia spectrumClinical psychologyPsychological Medicine
researchProduct

Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis

2023

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme.

SCHIZOPHRENIA SPECTRUMmedicine.medical_specialtyGENESpolygenic riskfirst-episode psychosiILLNESSinteraction contrast ratioChildhood traumaDOPAMINEFirst episode psychosisSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.MALTREATMENTMedicinefirst-episode psychosisABUSEPsychiatrySettore MED/25 - PsichiatriaApplied PsychologyTRAUMAENVIRONMENTbusiness.industrymedicine.diseaseschizophreniaPsychiatry and Mental healthSchizophreniaRELIABILITYPolygenic risk scoresynergistic effectsbusinessPsychological medicine
researchProduct

Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and …

2021

AbstractBackgroundFirst episode psychosis (FEP) patients who use cannabis experience more frequent psychotic and euphoric intoxication experiences compared to controls. It is not clear whether this is consequent to patients being more vulnerable to the effects of cannabis use or to their heavier pattern of use. We aimed to determine whether extent of use predicted psychotic-like and euphoric intoxication experiences in patients and controls and whether this differs between groups.MethodsWe analysed data on patients who had ever used cannabis (n = 655) and controls who had ever used cannabis (n = 654) across 15 sites from six countries in the EU-GEI study (2010–2015). We used multiple regres…

SYMPTOMSPoison control0302 clinical medicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.substance abuseApplied PsychologyPOPULATIONRISKeducation.field_of_studybiologyHuman factors and ergonomicsCannabis usePsychotomimeticSubstance abusePsychiatry and Mental healthSchizophreniaPsychotic-like experiencepsychotomimeticmedicine.drugmedicine.medical_specialtyDISORDERSPopulationFrequency of use03 medical and health sciencesFirst episode psychosisInjury preventionmedicineHumansAssociation (psychology)PsychiatryeducationSettore MED/25 - PsichiatriaDELUSIONAL IDEATIONEffects of cannabisMETAANALYSISCannabisCannabinoid Receptor Agonistsbusiness.industryPsychotic-like experiencesbiology.organism_classificationmedicine.disease030227 psychiatryschizophreniaMulti nationalPsychotic DisordersHallucinogensPOTENCYCannabisbusiness030217 neurology & neurosurgery
researchProduct

Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study.

2022

the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI) and FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS) (...)

Schizophrenia/geneticsEnvironmental effects on human beingsRisk factors in diseasesEpidemiologyPsicosipsychosiPathological psychologyGenes × environment interactionRisk FactorsSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.psychosocial stressorsHumanspsychosisPsychotic Disorders/geneticsSettore MED/25 - PsichiatriaInfluència del medi ambient en l'homeGenètica de la conductaFactors de risc en les malaltiesGenes × environment interactionsPublic Health Environmental and Occupational HealthPsychosespolygenic risk score for schizophreniaPsicopatologiaPsychiatry and Mental healthPsychotic DisordersBehavior geneticsSchizophreniaEsquizofrèniaGene-Environment Interaction
researchProduct

Development of the insight scale for affective disorders (ISAD): modification from the scale to assess unawareness of mental disorder.

2011

Abstract Background Research on insight in patients with mood disorders has grown in recent years. Several instruments to assess insight have been used, but most of them have been specifically designed for psychosis and may not appear relevant to mood disorders. The aim of the present study is to develop a short, multidimensional, reliable and valid scale to measure insight in patients with mood disorders, based on the Amador's Scale to Assess Unawareness of Mental Disorders (SUMD). Method A Delphi method was used to facilitate expert participation and ensure face and content validity. The SUMD structure and items were used as a reference in the scale development. A new scale with 17 items …

Self-assessmentAdultMalePsychosismedicine.medical_specialtySelf-AssessmentBipolar DisorderDelphi methodDiagnosis DifferentialContent validitymedicineHumansBipolar disorderAge of OnsetPsychiatryReliability (statistics)Depressive Disorder MajorPsychological TestsPsychopathologyMood DisordersReproducibility of ResultsAwarenessmedicine.diseaseDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthClinical PsychologyMood disordersPsychotic DisordersScale (social sciences)FemalePsychologyClinical psychologyJournal of affective disorders
researchProduct

Perceived stigma in patients affected by psychosis: Is there an impact on relapse?

2016

Introduction The World Health Organization (WHO) considers stigma of mental illness as a crucial problem (WHO, 2001). Stigma contributes to the onset (Morgan et al., 2010) and the outcome of people affected by schizophrenia (Himan, 2015). Objectives To evaluate the perception of patients affected by psychotic disorders of being stigmatized by the community. Aims To compare the perception of stigma among subgroups of patients at different stage of their disorder. Methods Thirty-five patients affected by a first-episode of psychosis (FEP) and 96 patients affected by chronic psychosis were recruited. The Devaluation of Consumers Scale (DCS) and the Devaluation of Consumer Families Scale (DCFS)…

Settore M-PSI/08 - Psicologia ClinicaSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.STIGMA PSYCHOSISSettore MED/25 - Psichiatria
researchProduct